Johan Lundberg
- Department of Clinical Neuroscience
- Centre for Psychiatry Research at CNS
- Molecular brain imaging, neuropsychopharmacology, depression and anxiety disorders – Johan Lundberg's research group
About me
Johan Lundberg, MD, PhD, is Professor of Psychiatry at the Department of Clinical Neuroscience, Karolinska Institutet, and Senior Physician at Northern Stockholm Psychiatry (SLSO), where he leads a research group in molecular brain imaging and neuropsychopharmacology.
The research asks a single clinical question from several directions: what changes in the brain, and in patients’ lives, when a psychiatric disorder like depression is treated effectively? The group combine three approaches to answer it.
Molecular imaging of treatment mechanisms. Using PET and MRI, the group studies how antidepressant treatments act on the human brain. A series of studies has suggested the serotonin 1B receptor as a point of change after treatment with SSRIs, ketamine and electroconvulsive therapy (ECT). More recent work examines synaptic density and neuroplasticity in depression using the SV2A radioligand [11C]UCB-J.
Clinical trials of new treatments. The group runs randomised, placebo-controlled trials of psilocybin for major depression. These include the PSIPET trial, which combines clinical outcomes with PET imaging, cerebrospinal fluid and blood biomarkers; its main clinical results were published in JAMA Network Open in 2026. The group also leads the multicentre CAPSI trial in patients with cancer-related depression. In addition, it studies the methods of psychedelic trials, including therapist training and the outcomes of control groups.
Real-world outcomes. Using Swedish health registers and total-population data from the Stockholm region, the group studies how depression and its treatments play out in routine care. Topics include ECT and rTMS outcomes, recovery and recurrence, transitions from unipolar depression to bipolar disorder, and healthcare use.
All three approaches rest on methodological rigour. The group develops and validates methods for quantifying PET data, including Bayesian modelling and reference-region approaches.
Johan Lundberg earned his MD (1998) and PhD (2006) at Karolinska Institutet. He became a specialist in psychiatry in 2007 and Docent in 2015, and was appointed Professor in 2025. He has supervised, or is currently supervising, 14 doctoral students and has published more than 100 peer-reviewed papers. He co-chairs the European College of Neuropsychopharmacology (ECNP) Psychedelics Research Network, contributes to the Swedish national guidelines for depression and anxiety, and is a co-founder of the Swedish National Quality Registry for ECT, where he sits on the steering committee.
Articles
- Article: MOLECULAR PSYCHIATRY. 2026;31(11):6351-6359Matheson GJ; Lundberg J; Garde M; Veldman ER; Tateno A; Ekman C-J; Arakawa R; Knudsen GM; Okubo Y; Ogden RT; Tiger M
- Article: NORDIC JOURNAL OF PSYCHIATRY. 2026;80(7):479-488Noda Y; Lundberg J; Nordenskjold A; Boden R
- Article: NEUROPSYCHOPHARMACOLOGY. 2026;51(10):1898-1901Paslawski W; Doyon D; Ekman CJ; Yngwe H; Mamula D; Zareba-Paslawska J; Beckman M; Xu Z-QD; Hokfelt T; Tiger M; Lundberg J; Svenningsson P
- Article: BJPSYCH OPEN. 2026;12(4):e158Sjogren HW; Lopez E; Lisinski A; Landen M; Lundberg J; Hieronymus F
- Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2026;46(6):1730-1738Garde M; Varnas K; Lundberg J; Svensson J; Farde L; Matheson GJ; Tiger M
- Article: ACTA PSYCHIATRICA SCANDINAVICA. 2026;153(6):649-655Hagsater SM; Nordenskjold A; Nordanskog P; Lundberg J; Ekman CJ; Hieronymus F; Boden R
- Article: JAMA NETWORK OPEN. 2026;9(5):e2612589Yngwe H; Plaven-Sigray P; Ekman CJ; Henje E; Berglund A; Tiger M; Beckman M; Lundberg J
- Article: EJNMMI RESEARCH. 2026;16(1):66Griffioen G; Tangen A; Veldman E; Svensson JE; Tiger M; Nord M; Andersson M; Sorjonen K; Varrone A; Halldin C; Varnas K; Borg J; Lundberg J
- Article: BMC MEDICAL EDUCATION. 2026;26(1):635Morel NS; Stenbaek DS; Lundberg J; Beckman M
- Journal article: NEUROSCIENCE APPLIED. 2026;5:106904Lopez E; Lundberg J; Hieronymus F; Beckman M; Yngwe H; Ekman CJ; Tiger M; Edvall N
- Article: IMAGING NEUROSCIENCE. 2025;3:imag.a.1011Matheson GJ; Lundberg J; Garde M; Veldman ER; Tateno A; Okubo Y; Tiger M; Ogden RT
- Article: JAMA NETWORK OPEN. 2025;8(7):e2524119Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-AnalysisHieronymus F; Lopez E; Werin Sjogren H; Lundberg J
- Article: ACTA PSYCHIATRICA SCANDINAVICA. 2025;151(5):625-633Bostrom AED; Cars T; Hellner C; Lundberg J
- Article: PSYCHIATRY RESEARCH. 2025;344:116341Bostrom AED; Andersson P; Wachtel LE; Jarbin H; Jokinen J; Lundberg J
- Article: JOURNAL OF AFFECTIVE DISORDERS. 2024;362:96-103Gannedahl A; Bjorkholm C; Leval A; Cars T; Hellner C; Lundberg J
- Article: JAMA PSYCHIATRY. 2024;81(9):863-869Bostrom AED; Cars T; Hellner C; Lundberg J
- Article: JAMA NETWORK OPEN. 2024;7(7):e2422738Gillving C; Ekman CJ; Hammar A; Landen M; Lundberg J; Rad PM; Nordanskog P; von Knorring L; Nordenskjold A
- Article: JOURNAL OF ECT. 2024;40(2):88-95Strandberg P; Nordenskjold A; Boden R; Ekman CJ; Lundberg J; Popiolek K
- Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2024;27(5):pyae021Garde M; Matheson GJ; Varnaes K; Svenningsson P; Hedman-Lagerloef E; Lundberg J; Farde L; Tiger M
- Review: LAKARTIDNINGEN. 2024;121:23195López E; Yngwe H; Beckman M; Tiger M; Hieronymus F; Lundberg J
- Show more
All other publications
- Preprint: BIORXIV. 2026Haver G; Matheson GJ; Yngwe H; Andersson M; Edvall NK; Noergaard M; Zanderigo F; Schmidt M; Bartlett EA; Miller JM; Cselenyi Z; Tiger M; Beckman M; Ekman C-J; Lundberg J
- Preprint: MEDRXIV. 2026Yngwe H; Plaven Sigray P; Andersson M; Bolin M; Beckman M; Ekman C-J; Tiger M; Lundberg J
- Preprint: RESEARCH SQUARE. 2026Kjellgren A; Lundberg J; Yngwe H; Ekman CJ; Tiger M; Ljunglöf T; Stridh F; Beckman M
- Preprint: RESEARCH SQUARE. 2026Stridh A; Eriksson J; Lundberg J; Svensson JE; Matheson GJ; Veldman ER; Varrone A; Jokinen J; Tiger M
- Preprint: RESEARCH SQUARE. 2025Griffioen G; Hildalgo N; Sorjonen K; Andersson M; Tangen Ä; Chin L; Lundberg J; Halldin C; Bölte S; Borg J
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2025;28:i35-i36Griffioen-Jarfalk G; Bolin M; Stephanov V; Cervenka S; Castelo-Branco M; Martins R; Lundberg J; Mehra C; Howes O; Murphy D; Bolte S; Farde L; Borg J
- Preprint: BIORXIV. 2024;BIORXIVMatheson GJ; Lundberg J; Gärde M; Veldman ER; Tateno A; Okubo Y; Tiger M; Ogden RT
- Letter: JOURNAL OF ECT. 2024;40(2):140-141Popiolek K; Arnison T; Boden R; Ekman CJ; Lundberg J; Strandberg P; Nordenskjold A
- Letter: JAMA PSYCHIATRY. 2024;81(4):426Bostroem AED; Andersson P; Lundberg J
- Letter: JACC-JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2023;82(19):e177Bostrom AED; Lundberg J
- Preprint: MEDRXIV. 2023Spulber S; Elberling F; Ceccatelli S; Gärde M; Tiger M; Lundberg J
- Editorial: LANCET. 2023;401(10378):714-716Butlen-Ducuing F; McCulloch DE-W; Haberkamp M; Mattila T; Balkowiec-Iskra E; Aislaitner G; Balabanov P; Lundberg J; Stenbaek DS; Elferink A; Knudsen GM; Thirstrup S
- Conference publication: PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE ... SCIENTIFIC MEETING AND EXHIBITION.. 2022Sitnikov R; Tiger M; Lundberg J
- Book chapter: TRANSLATIONAL RESEARCH METHODS FOR MAJOR DEPRESSIVE DISORDER: NEUROMETHODS. 2022;p. 227-240Tiger M; Lundberg J
- Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021;53:S636-S637Bjorkholm C; Gannedahl A; Leval A; Cars T; Sjalin M; Hellner C; Lundberg J
- Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(1_SUPPL):169-170Andersson M; Varnas K; Halldin C; Borg J; Farde L; Lundberg J
- Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2020;40:S149-S150Bjorkholm C; Gannedahl A; Leval A; Rive B; Cars T; Sjalin M; Van Sanden S; Hellner C; Lundberg J
- Preprint: BIORXIV. 2020Freiburghaus T; Svensson J; Matheson G; Plavén-Sigray P; Lundberg J; Farde L; Cervenka S
- Letter: NEUROIMAGE. 2020;207:116371Svensson JE; Schain M; Plaven-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
- Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:S172Lundberg J; Hellner C; Leval A; Sjalin M; Ek M; Gannedahl A; Tiihonen J; Loov SA; Cars T
- Show more
Grants
- Improved understanding and prevention of suicide in depression through integration of genetic and epidemiological data in the Stockholm MDD cohortALF Medicin1 January 2026 - 31 December 2028
- Linking synaptic density with changes in brain network activity.Hjärnfonden1 July 2025 - 31 December 2027
- Swedish Research Council1 December 2024 - 30 November 2028The purpose of this study is to test the hypothesis of increased antidepressant efficacy of accelerated intermittent theta-burst stimulation (aiTBS) in depression through concomitant modulation of the N-methyl-D-aspartate receptor (NMDAR). The specific aim is to evaluate the effect of augmentation with the partial NMDAR agonist D-cycloserine during aiTBS for depressive symptoms in a placebo controlled randomized controlled trial. In this multicenter study we will recruit 90 patients, 18 years and older with an ongoing major depressive episode referred for clinical iTBS. Study participants will be randomized to receive either 100 mg D-cycloserine or placebo at each treatment day with aiTBS (6 sessions/day) in a double-blinded fashion during nine week-days. Primary outcome is change in depressive symptoms on the Montgomery–Åsberg Depression Rating Scale (MADRS) after the intervention. Secondary outcomes are change in Clinical Global Impression, as well as in weekly patient reported outcomes of depressive symptoms, and side-effects, including a four-week and six-month follow-up. We will also explore if the effects of D-cycloserine is more pronounced in patients with impaired neuroplasticity. If efficacy is demonstrated D-cycloserine augmented aiTBS could readily be implemented in clinical practice to decrease the disease burden of treatment resistant depression. Further, it may also serve as a long-awaited inpatient treatment alternative for rapid depressive symptom control.
- Swedish Research Council1 January 2024 - 31 December 2025
- Swedish Cancer Society1 January 2024A third of those who get cancer also develop it Depression. Despite the special circumstances of these patients, with concomitant cancer treatment, reduced quality of life and often expected shortened lifespan related to the cancer itself, there is no specific antidepressant treatment introduced in care. A single dose of psilocybin has shown a rapid (within days) and long-term (months to years) antidepressant effect in several small studies in which different cancer groups included. There is still a lack of good studies to introduce the treatment in clinical practice. There is also a lack of knowledge about which patients benefit of this particular treatment. 100 patients with cancer and depression are randomized to treatment with pslicybin or placebo i four different regions in Sweden during 2024-2025. We are investigating the antidepressant effect as well side effects 6 weeks after treatment and after six months. All patients submit blood samples and undergoes EEG examination before and six weeks after the treatment. The 25 patients participating in The Stockholm region is also examined with three other more demanding methods, MEG, fMRI and PET, to be able to create a simple measure where we can predict which patients with the help of blood tests and EEG who benefit most from psliocybin even before treatment. All this information will be used to carry out a so-called phase three study of psilocybin in cancer-related depression, where we also can refine the prognostic tool, blood tests and EEG, to see which patients benefit the most the treatment. After that, this treatment, together with the prognosis tool, can be introduced in usual clinical care. We think it can happen in 2031.
- Swedish Research Council1 January 2023 - 31 December 2026Background: The age standardised rate of yearly new cancer cases is 190/100 000 globally, by WHO. 30-40% of these will develop depression. There is currently no specific antidepressant treatment regime implemented in the cancer population. This is in spite of the specific needs given by concurrent cancer treatments, limited quality of life from the cancer per se and the often limited life expectancy from a cancer disease. A single dose of psilocybin combined with 3 hours of psychological support has shown rapid (within days) and long term (months or years) antidepressant effect in several small studies in different cancer populations. Large, well designed RCTs are still lacking, as is response predictors for treatment guidance. I am PI of the first RCT of psilocybin treament of depression in Sweden, expected to end randomisation in june 2022. CAPSI: 100 patients with cancer and depression will be randomised to psilocybin or active placebo (2:1) at 4 different regions in Sweden during 2024-2025. Primary end point is depressive symptoms 6 weeks post dose and follw up is 6 months. All subjects will undergo EEG and blood sampling, a subsample (n=50) will also undergo MEG and fMRI, and 25 of them also PET, in order to develop a EEG proxy response signature. Together with markers in blood we will develop a predictor model for psilocybin treatment response. All data will be used to motivate a phase three study with the same PICO and further development of the response markers.
- Swedish Research Council1 January 2023 - 31 December 2026While the selective serotonin reuptake inhibitors (SSRIs) are first line of treatment of depression, 30% of patients do not respond adequately. Adding an atypical antipsychotic agent to the SSRI may lead to a marked response in these cases, this having become a recommended strategy. Antipsychotic drugs are, however, marred by serious side effects, such as motor impairment, apathy, and the metabolic syndrome. OSU6162 is a dopamine stabilizer developed by Nobel prize winner Arvid Carlsson which bears pharmacological similarities to atypical antipsychotics, but which, according to experimental and clinical studies (where it has been tested mainly for the treatment of fatigue), is more activating than these, and entirey devoid of their side effects. A network of clinicians in Gothenburg, Kungälv, Lund, Stockholm, and Uppsala will now perform a randomized, 5-center, placebo-controlled trial aiming to assess the efficacy and tolerability of OSU6162 as add-on (flexible dose6 weeks of treatmentn=80 per group) in patients who have not responded to six weeks of treatment with an SSRI or a serotonin and noradrenaline reuptake inhibitor (SNRI). Mixed model statistics will be used to compare the groups with respect to the sum score for 6 core items of the Hamilton Depression Rating Scale at week 6. First patient first visit: Q1/2023last patient last visit: Q4/2025. Patient benefit: an effective and tolerable treatment for SSRI-resistant depression is an important unmet medical need.
- Swedish Research Council1 January 2022 - 31 December 2024
- Swedish Research Council1 January 2017 - 31 December 2019
- Swedish Research Council1 January 2017 - 31 December 2019
- Swedish Research Council1 January 2014 - 31 December 2016
- Swedish Research Council1 January 2014 - 31 December 2019
Employments
- Professor/Senior Physician, Psychiatry, Department of Clinical Neuroscience, Karolinska Institutet, 2025-
- Adjunct Professor, Department of Clinical Neuroscience, Karolinska Institutet, 2022-2025
Degrees and Education
- Docent, Karolinska Institutet, 2015
- Doctor Of Philosophy, Department of Clinical Neuroscience, Karolinska Institutet, 2006
- University Medical Degree, Karolinska Institutet, 1998